These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17824591)

  • 1. A model of effective health policy: the 1983 Orphan Drug Act.
    Reaves ND
    J Health Soc Policy; 2003; 17(4):61-71. PubMed ID: 17824591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution and current status of the Orphan Drug Act.
    Asbury CH
    Int J Technol Assess Health Care; 1992; 8(4):573-82. PubMed ID: 1464479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Orphan Drug Act. The first 7 years.
    Asbury CH
    JAMA; 1991 Feb; 265(7):893-7. PubMed ID: 1992188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act.
    Thamer M; Brennan N; Semansky R
    J Health Polit Policy Law; 1998 Apr; 23(2):265-90. PubMed ID: 9565894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R&D policy, agency costs and innovation in personalized medicine.
    Yin W
    J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Orphan drugs].
    Kolár J; Chalabala M; Srámková H
    Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market incentives and pharmaceutical innovation.
    Yin W
    J Health Econ; 2008 Jul; 27(4):1060-1077. PubMed ID: 18395277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical policy and innovation for rare diseases: A narrative review.
    Alonso Ruiz A; Large K; Moon S; Vieira M
    F1000Res; 2023; 12():211. PubMed ID: 38778810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.
    Herder M
    Account Res; 2013; 20(4):227-69. PubMed ID: 23805831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expansion of the Priority Review Voucher Program Under the 21
    Sinha MS; Jain N; Hwang T; Kesselheim AS
    Am J Law Med; 2018 May; 44(2-3):329-341. PubMed ID: 30106661
    [No Abstract]   [Full Text] [Related]  

  • 13. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
    Arno PS; Bonuck K; Davis M
    Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orphan drug product regulation--United States.
    Haffner ME
    Int J Clin Pharmacol Ther; 2002 Feb; 40(2):84-8. PubMed ID: 11862977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
    Kesselheim AS; Treasure CL; Joffe S
    PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts.
    Trouiller P; Battistella C; Pinel J; Pecoul B
    Trop Med Int Health; 1999 Jun; 4(6):412-20. PubMed ID: 10444316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
    Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orphan drug development in the United States.
    Groft SC
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.